
Abstract Objectives This study aimed to evaluate treatment persistence and safety following subcutaneous methotrexate (MTX) initiation in Japanese patients with rheumatoid arthritis and clinical outcomes after direct switching from oral to subcutaneous MTX. Methods We retrospectively studied 101 patients with rheumatoid arthritis initiating subcutaneous MTX. Efficacy and safety were analysed in patients switching because of adverse events. The primary endpoint was the 26-week retention rate. Results Gastrointestinal intolerance was the commonest reason for switching from oral to subcutaneous MTX. Overall retention rate was 87.1% (88/101). Among switchers, the 26-week retention rate was 92.0% (81/88), and the MTX dose increased in 46.6% (41/88). In patients not receiving biologic or targeted synthetic disease-modifying anti-rheumatic drugs at switching (n = 50), the retention rate was 96.0% (48/50), and the mean MTX dose increased (10.3 ± 2.8 to 12.0 ± 2.8 mg/week; P < .0001). The Clinical Disease Activity Index improved by week 26 (13.2 ± 10.1 to 8.2 ± 7.8; P < .0001), with 30.0% (15/50) achieving remission. Conclusions Switching from oral to subcutaneous MTX in patients with rheumatoid arthritis who are intolerant to oral MTX may enable continued treatment and dose optimization and be associated with improved disease activity.
Abstract Objectives To develop quality indicators for evaluating and improving care for patients with systemic sclerosis. Methods We developed quality indicators using a modified RAND/University of California Los Angeles Appropriateness Method. A systematic literature review identified candidate items from previous systemic sclerosis quality indicator studies and clinical practice guidelines. A multidisciplinary expert panel of 10 physicians specializing in rheumatology, dermatology, pediatrics and cardiology completed two anonymous rating rounds, with item revision after a web-based panel meeting. One physiotherapist and one patient with systemic sclerosis participated as non-voting observers. Items with a median appropriateness score of 7 or higher and strict agreement were retained. Results The review identified 86 candidate items from three quality indicator studies and 23 clinical practice guidelines. After first-round rating and discussion, 78 revised items underwent second-round evaluation. Thirty-three indicators met the prespecified selection criteria. The final set covered general management, lung, gastrointestinal, kidney, heart, pulmonary hypertension, vascular, muscle, rehabilitation, and pediatric domains. Conclusions We developed a 33-item quality indicator set for systemic sclerosis through a structured consensus process. The indicators may support quality assessment and improvement in Japanese clinical practice.
Abstract Objective To describe transitional care for juvenile rheumatic and musculoskeletal disorders in Japan and identify barriers/facilitators to collaboration between departments and facilities. Methods We conducted a cross-sectional web-based survey in Japan (19 February–26 April 2025) targeting councillors/board members of the Japan College of Rheumatology and the Paediatric Rheumatology Association of Japan. Fisher’s exact tests and odds ratios were used for comparing adult and paediatric rheumatology services, and five major cities and others. Sparse cells were examined using Firth’s penalised logistic regression. Results Of 159 submitted questionnaires, 122 were valid. Over 70% managed transitioned patients in the past 3 years. Respondents perceived that transition-related activity had increased (34.9%), whereas barriers remained unchanged (68.6%). Among adult rheumatology declining transitioned patients, 83.3% reported ‘no referral received’. Awareness/ever utilised was 73.3%/24.4% for the Transition Support Guide and 45.3%/23.3% for MIRAI TALK, a patient-held transition communication/support tool for paediatric rheumatic diseases. Paediatrics showed higher awareness and ever utilisation of both tools than adult rheumatology. Preconception care awareness was high, with 68.9% implementation and with significantly less frequent male-targeted counselling in adult rheumatology. Awareness of transitional care support centres was limited (one-third) and lower in adult rheumatology. Conclusion Among surveyed rheumatology specialists, transition-related activity was perceived to have increased, but referral gaps, low adult-side tool uptake, and limited consultation pathways persist.
Background Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive joint destruction and significant impairment of health-related quality of life (HRQoL). The receptor activator of nuclear factor-kappa B ligand (RANKL)/osteoprotegerin (OPG) pathway plays a pivotal role in bone metabolism and joint destruction in RA. However, the clinical value of serum OPG and RANKL levels for identifying a low physical HRQoL status in RA patients remains unclear. This study aimed to develop and internally validate a nomogram model incorporating serum OPG and RANKL to estimate the probability of a low physical HRQoL status in RA patients. Methods This retrospective cross-sectional study enrolled 324 RA patients from January 2022 to December 2025. Patients were randomly divided into training (n = 227) and internal validation (n = 97) cohorts at a 7:3 ratio. HRQoL was assessed using the Medical Outcomes Study 36-Item Short-Form Health Survey, with a low physical HRQoL status defined as Study 36-Item Short-Form Health Survey Physical Component Summary score <40 at the assessment time point. Serum OPG and RANKL levels were measured by an enzyme-linked immunosorbent assay. Univariate and multivariate logistic regression analyses were performed to identify factors associated with a low physical HRQoL status. Age and sex were included as clinically important adjustment variables, the Health Assessment Questionnaire Disability Index was incorporated to account for functional disability, and the RANKL/OPG ratio was not entered into the primary multivariate model together with its components to avoid mathematical collinearity. A nomogram was constructed and internally validated using split-sample assessment, receiver operating characteristic curves, calibration plots, and decision curve analysis. Results Among the 324 patients, 138 (42.6%) had low physical HRQoL status. In the primary multivariate model, the Health Assessment Questionnaire Disability Index [odds ratio (OR) = 2.18, 95% confidence interval (CI): 1.48-3.22, P < .001)], serum RANKL (OR = 1.76, 95%CI: 1.25-2.48, P = .001), serum OPG (OR = 0.75, 95%CI: 0.59-0.96, P = .022), the Disease Activity Score 28 with erythrocyte sedimentation rate (OR = 1.48, 95%CI: 1.05-2.08, P = .025), disease duration (OR = 1.36, 95%CI: 1.04-1.78, P = .024), and CRP (OR = 1.24, 95%CI: 1.01-1.52, P = .042) were associated with low physical HRQoL status after adjustment for age and sex. The nomogram demonstrated excellent discrimination with an area under the receiver operating characteristic curve of 0.881 (95%CI: 0.835-0.927) in the training cohort and 0.864 (95%CI: 0.792-0.936) in the internal validation cohort. Calibration curves showed good agreement between predicted and observed probabilities. Decision curve analysis confirmed a substantial clinical net benefit across clinically relevant threshold probabilities. Conclusions This study developed and internally validated a nomogram model integrating serum OPG and RANKL levels, functional disability, inflammatory activity, and disease duration for identifying low physical HRQoL status in RA patients. The model demonstrates robust discrimination, calibration, and clinical utility, providing clinicians with a practical tool for individualized risk stratification and facilitating earlier supportive and disease-control interventions.
Objectives This study examined whether adopting the Boolean 2.0 remission criteria results in the inclusion of patients with a higher burden of residual symptoms (RS) in rheumatoid arthritis. It also aimed to characterize differences in RS burden across remission definitions. Methods This cross-sectional, single-centre study included 400 consecutive patients with rheumatoid arthritis. RSs were assessed using the Okomarigoto Sheet (OS), which evaluates pain, morning stiffness, and fatigue. Clinical remission was defined using the Disease Activity Score in 28 joints with C-reactive protein, Clinical Disease Activity Index, Simplified Disease Activity Index, and Boolean 1.0 and 2.0 criteria. The primary outcome was the proportion of patients achieving OS = 0. Mixed-effects logistic regression and subgroup analyses were conducted to compare RS burden across remission definitions. Results The proportion of patients achieving a complete absence of RSs differed across remission definitions, with the highest rate observed in Boolean 1.0 remission (52.7%), followed by Boolean 2.0 (45.0%), and the Disease Activity Score in 28 joints with C-reactive protein (37.5%). Compared with Boolean 1.0 remission, patients meeting Boolean 2.0 but not Boolean 1.0 criteria had significantly higher total and domain-specific OS scores (all P < .001). Similar findings were observed among patients achieving the Disease Activity Score in 28 joints with C-reactive protein remission but not Boolean 1.0 remission. Mixed-effects logistic regression indicated no significant difference between Boolean 1.0 and Boolean 2.0 remission in achieving OS = 0. Conclusions The RS burden in rheumatoid arthritis varies depending on the remission definition. Boolean 2.0 remission expands the classification of remission and is associated with higher multidimensional RS scores than Boolean 1.0 remission.